Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122258 | 0.82 | CYP11B2 (0.55) | CYP11B2CYP11B1TSHRKDM4EGAA | |
| SCHEMBL4109519 | 0.81 | CYP11B2 (0.54) | CYP11B2CYP11B1TSHRKDM4EGAA | |
| SCHEMBL27628580 | 0.79 | TSHR (0.50) | CYP11B2CYP11B1TSHRKDM4EGAA | |
| SCHEMBL4127465 | 0.77 | MEN1 (0.42) | TSHRALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL4118704 | 0.77 | CYP11B2 (0.53) | CYP11B2CYP11B1TSHRKDM4EGAA | |
| SCHEMBL4123147 | 0.77 | CYP11B2 (0.53) | CYP11B2CYP11B1TSHRKDM4EGAA | |
| SCHEMBL4110896 | 0.77 | CYP11B2 (0.54) | CYP11B2CYP11B1TSHRKDM4EGAA | |
| SCHEMBL27648606 | 0.77 | TSHR (0.48) | CYP11B2CYP11B1TSHRKDM4EGAA | |
| SCHEMBL4109515 | 0.75 | RAB9A (0.45) | TSHRKDM4EGAAALDH1A1HSD17B10 | |
| SCHEMBL4112681 | 0.75 | CYP11B2 (0.50) | CYP11B2CYP11B1TSHRKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1566378-B1 | ISOINDOLINE DERIVATIVE | MARUISHI PHARMA (JP) | 2012-08-15 | — | — | EP | disclosed |
| CN-100548980-C | The isoindoline derivative | MARUISHI PHARMA (JP) | 2009-10-14 | — | — | CN | disclosed |
| US-20090170835-A1 | ISOINDOLINE DERIVATIVES | MARUISHI PHARMACEUTICAL CO., LTD. | 2009-07-02 | — | — | US | disclosed |
| US-7521451-B2 | Isoindoline derivative | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20060052392-A1 | e.g. 5,6-dimethyl-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione;intravenous, water-soluble compounds useful for manufacturing an anasthetic, sedative agents; side effect reduction | MARUISHI PHARMACEUTICAL CO., LTD | 2006-03-09 | — | — | US | disclosed |
| CN-1741995-A | Isoindoline derivative | MARUISHI PHARMA (JP) | 2006-03-01 | — | — | CN | disclosed |
| EP-1566378-A1 | ISOINDOLINE DERIVATIVE | Maruishi Pharmaceutical Co., Ltd. (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052392-A1 | e.g. 5,6-dimethyl-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione;intravenous, water-soluble compounds useful for manufacturing an anasthetic, sedative agents; side effect reduction | CYP3A5, OPRD1, CYP3A7 | CYP11B2 204/4885CYP11B1 286/4885TSHR 4041/4885 |
| US-20090170835-A1 | ISOINDOLINE DERIVATIVES | OPRD1, OPRK1, OPRL1 | CYP11B2 251/4885CYP11B1 597/4885TSHR 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.